Validation with systems biology using reweighted 20 types of cancer signature genes revealed that CCNB2 isthe only common target in BC and its related PBMCs, which was further validated by qRT-PCR implying a significantincrease in the level of CCNB2in the BC patients. Here, CCNB2 is linked to cancer.